Patents by Inventor Christopher Bauer

Christopher Bauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
    Patent number: 5738849
    Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
    Type: Grant
    Filed: February 4, 1994
    Date of Patent: April 14, 1998
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
  • Interleukin-3 (IL-3) mutant polypeptides and their recombinant production
    Patent number: 5677149
    Abstract: Disclosed are recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins) having one to three amino acid substitutions in the core sequence (residues 15-125) of the native (133 amino acid) sequence of hIL-3. The muteins of the invention may also have deletions of 1 to 14 amino acids at the N-terminus and/or 1 to 15 amino acids at the C-terminus relative to the native hIL-3 sequence. Also within the scope of the invention are recombinant expression systems and methods for making the mutant hIL-3 polypeptides, as well as pharmaceutical compositions and methods for using them. The disclosed hIL-3 mutant polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile in therapeutic applications.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: October 14, 1997
    Assignee: G.D. Searle & Co.,
    Inventors: S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter Olins, Kumnan Paik, Joseph Polazzi, John Warren Thomas
  • Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods
    Patent number: 5604116
    Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids 119 to 133 have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.
    Type: Grant
    Filed: April 6, 1995
    Date of Patent: February 18, 1997
    Assignee: G. D. Searle & Co.
    Inventors: S. Christopher Bauer, Mark A. Abrams, Sarah R. Braford-Goldberg, Maire H. Caparon, Alan M. Easton, Barbara K. Klein, John P. McKearn, Peter Olins, Kumnan Paik, John W. Thomas